We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Phosphorylation of Tau Protein Inhibits Amyloid-beta Toxicity in Alzheimer’s Model

By Gerald M. Slutzky, PhD
Posted on 29 Nov 2016
A team of Australian Alzheimer's disease (AD) researchers have presented evidence suggesting that phosphorylation of tau protein in the early stages of the disease acts to protect against the toxicity of amyloid-beta (Abeta) plaques, and that this protective effect disappears as the disease progresses.

The prevailing idea among AD researchers has been that Abeta induced phosphorylation of tau, which in turn triggered the neuronal dysfunction that characterized the disease.

Investigators at the University of New South Wales (Sydney, Australia) worked with Alzheimer's disease mouse models and samples of brain tissue obtained from AD patients. More...
They reported in the November 18, 2016, issue of the journal Science that at least in early stages of the disease, site-specific phosphorylation of tau inhibited Abeta toxicity. This specific tau phosphorylation was mediated by the neuronal enzyme p38gamma (p38 mitogen-activated protein kinase) and interfered with postsynaptic toxic signaling complexes engaged by Abeta.

Depletion of p38gamma increased the severity of neuronal circuit aberrations, cognitive deficits, and premature lethality in a mouse model of AD, whereas increasing the activity of p38gamma abolished these deficits. Furthermore, mimicking site-specific tau phosphorylation alleviated Abeta-induced neuronal death and offered protection from its toxicity.

"This study has completely changed our understanding of what happens in the brain during the development of Alzheimer's disease," said senior author Dr. Lars Ittner, professor of medicine at the University of New South Wales. "Amyloid-beta induces toxicity in the neurons but the first step in tau phosphorylation is actually to decrease this toxicity. This is a completely new mindset; that the reason tau becomes modified is actually to protect from damage. We found that p38gamma, which initially offers protection, fades away early in the brains of people with AD, suggesting a loss of protection."

"We set out to find mediators of this progression, which led us quickly to our surprising finding. It was the opposite of what we expected. It was only when we changed our view of the process involved in the development of AD that these results started to make sense," said Dr. Ittner. "We used mice to screen for a very specific toxicity that we knew from previous work is involved in the progression of the disease. Part of our study involved reintroducing p38gamma and increasing its activity. We saw that, in mice, it could prevent memory deficits from happening, so it has true therapeutic potential. If we can stimulate that activity, we may be able to delay or even halt the progression of Alzheimer's disease."

Related Links:
University of New South Wales


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new RABTA sets a high standard in laboratory diagnostics (Photo courtesy of Randox)

Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics

A state-of-the-art analyzer combines advanced technology with exceptional efficiency to meet the demanding needs of modern laboratories. Randox Toxicology (Antrim, Ireland) has launched its pioneering... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.